Introduction
▪ Growth hormone (GH) excess in acromegaly is associated with higher mortality and morbidity ▪ With improved treatment for acromegaly, many studies have demonstrated latest mortality rates to be improving and comparable to the general population (Schofl 2012 Eur J Endocrinol; Varadhan 2016 Pituitary) ▪ Though the SMR for acromegaly per se is improving with time, The mortality rates remain high largely due to cancers and circulatory disease (Esposito 2018 Eur J Endocrinol)
▪ Acromegaly is associated with significant morbidity (Dekkers 2008 J Clin Endocrinol Metab) ▪ There are not many studies that have looked at the predictors of morbidity associated with acromegaly ▪ Development of comorbidities such as cardiovascular events and cancers are an important cause of mortality (Varadhan 2016 Pituitary) ▪ A recent study used IgF1 as a marker but this may not be available in all patients who have been follow up for more than 2 decades (Jayasena 2011 Clin Endocrinol) ▪ The duration of diabetes preceding the diagnosis of acromegaly is unaccounted for and could contribute to morbidity of acromegaly (Vallette 2013 Clin Endocrinol) ▪The frequency of pituitary surgery to aim for cure for this condition has been progressively increasing (Esposito 2018 Eur J Endocrinol) ▪Patients with acromegaly continue to have significant comorbidities, especially cancers, cardiovascular diseases, diabetes and hypopituitarism, which can account for a significant financial burden on health care system (Lesen 2017 Eur J Endocrinol)
Aim
The aim of the study was to assess the differences in mortality and morbidity associated with active acromegaly compared to patients in whom disease control was achieved ▪ Data on mortality and CVE and duration to the events were calculated ▪ IgF-1 was not included in this analysis due to lack of sufficient data
Results

Discussion
Conclusion
▪ Mortality rates from acromegaly were higher in patients with active disease ▪ Disease burden from acromegaly is significantly high in both 'controlachieved' as well as 'active disease' group; however the duration to develop these complications can be prolonged by achieving control ▪ The various available treatment options would need to be explored, with surgery being the preferred choice, to aim to achieve biochemical control of acromegaly to reduce the risk of complications
Results
▪ The initial GH at diagnosis and macroadenomas were significantly higher in the active disease group, suggesting more severe disease ▪ The proportion of patients operated was higher in the group were control achieved, again showing surgery as the most successful form of treatment ▪ The number of treatment modalities required to achieve control was higher compared to group where control not achieved, suggesting that a more aggressive approach may be helpful ▪ Though CVE was equal in both groups, the duration to achieve control was higher in patients where control achieved, again highlighting the benefit of curing acromegaly ▪ The mortality rates were higher in the active disease group ▪ Though the total number of treatment modalities was higher, the proportion suffering with further pituitary axes failure was comparable between the two groups 
